Rapport Therapeutics, Inc

RAPPNASDAQ · Pharmaceutical Preparations

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

48.0M

on 2026-06-30, from 36.6M on 2024-06-30 10-Q ↗

a raise that quarter, at its price

Newest

No limit

S-3ASR of 2026-03-10. An automatic shelf: the form sets no dollar limit. None sold under it to 2026-10-05. S-3ASR ↗

$110.0M

Leerink Partners, agreement of 2026-01-07. No at-the-market sales statement read from a 10-Q or 10-K. 424B5 ↗

Warrants

The 10-Q filed 2026-08-05 is not read yet.

Cash

18 quarters

$436.1M on 2026-06-30 ÷ $24.2M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised
Date	What	Shares	Price	Gross	Filing
2025-09-09	Public offering	9,615,385	$26.00	$250.0M	424B5 ↗